NFJ Investment Group LLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

NFJ Investment Group LLC bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, Holdings Channel reports. The firm bought 278,792 shares of the biotechnology company’s stock, valued at approximately $2,788,000.

A number of other large investors have also bought and sold shares of the business. Larson Financial Group LLC increased its holdings in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter worth $101,000. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals in the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $98,000. 85.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Citizens Jmp boosted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Stock Down 4.1%

BCRX stock opened at $9.66 on Friday. The company has a market cap of $2.47 billion, a P/E ratio of -6.44 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The business has a fifty day moving average of $9.61 and a 200-day moving average of $8.93.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 earnings per share. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.